CWR22Rv1-AR-EK cell line

Catalogue number: 154854
Sub-type: Continuous
Images:

Contributor

Inventor: Luke Gaughan
Institute: Newcastle University
Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: CWR22Rv1-AR-EK cell line

Alternate name: AR-V

Class:
Conjugate:
Description: Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR).The CWR22Rv1-AR-EK (Androgen Receptor-Exon Knockout) cell line is a prostate cancer cell line which is knockout for FL-AR (by CRISPR) but retains expression of all endogenous AR-Vs making it a valuable model for the study of receptor splice variants. This new derivative is dependent upon AR-Vs for growth and is refractory to all FL-AR-targeting agents. CRISPR edited CWR22Rv1 cells.
Purpose:
Parental cell: CWR22Rv1
Organism: Human
Tissue:
Model: Knock-In
Gender:
Isotype:
Reactivity:
Selectivity:
Host:
Immunogen:
Immunogen UNIPROT ID:
Sequence:

Growth properties:
Production details: CRISPR-derived cell line that has lost expression of full length androgen receptor (FL-AR), but retains all endogenous androgen receptor variants (AR-Vs). Two gRNAs were designed to target distinct loci within exon 5 of the AR gene. To knock-in a stop codon into exon 5 of the AR locus, a 180 bp ssODN template was designed containing a central TAA sequence and flanked by 75 bp 5Ä?Ë???Â???Â? and 3Ä?Ë???Â???Â? termini 100% complementary to the AR gene sequence.
Formulation:
Recommended controls: CWR22Rv1 parental line
Bacterial resistance:
Selectable markers:
Additional notes: CRISPR edited CWR22Rv1 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can pr...

Target details

Target: Androgen Receptor variants

Target alternate names:

Target background:

Molecular weight:

Ic50:

Applications

Application:
Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

Format: Frozen
Concentration:
Passage number:
Growth medium: RPMI 1640 media supplemented with 10% foetal calf serum (FCS) and 5% L-

glutamine at 37??Â°C
Temperature:
Atmosphere:
Volume:
Storage medium:
Storage buffer:
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice

Related tools

Related tools:

References

References: